Ruth O’Regan

1.2k total citations
34 papers, 907 citations indexed

About

Ruth O’Regan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Ruth O’Regan has authored 34 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 13 papers in Cancer Research. Recurrent topics in Ruth O’Regan's work include Breast Cancer Treatment Studies (12 papers), Advanced Breast Cancer Therapies (10 papers) and HER2/EGFR in Cancer Research (7 papers). Ruth O’Regan is often cited by papers focused on Breast Cancer Treatment Studies (12 papers), Advanced Breast Cancer Therapies (10 papers) and HER2/EGFR in Cancer Research (7 papers). Ruth O’Regan collaborates with scholars based in United States, Italy and Switzerland. Ruth O’Regan's co-authors include Sheryl G. A. Gabram, Mary Jo Lund, Ralph J. Coates, Maksym Yezhelyev, Peggy L. Porter, Elaine W. Flagg, Katrina F. Trivers, J. William Eley, Otis W. Brawley and Brian Leyland‐Jones and has published in prestigious journals such as Journal of Clinical Oncology, Nano Letters and Cancer Research.

In The Last Decade

Ruth O’Regan

28 papers receiving 887 citations

Peers

Ruth O’Regan

ONCOL

PRM

GENET

Hirokazu Tanino Japan

Renquan Lu China

Liheng Zhou China

Tatsuya Manabe Japan

Carmen M. Barnés United States

Ralph R. Weichselbaum United States

Ruth A. Modzelewski United States

En‐Chi Hsu United States

Chelsea Mayoh Australia

Jinlu Ma China

Hirokazu Tanino Japan

Ruth O’Regan

415 ×0.9

ONCOL

176 ×0.5

324 ×1.4

208 ×0.9

PRM

83 ×0.7

GENET

Citations per year, relative to Ruth O’Regan Ruth O’Regan (= 1×) peers Hirokazu Tanino

Countries citing papers authored by Ruth O’Regan

Since Specialization

Citations

This map shows the geographic impact of Ruth O’Regan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruth O’Regan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruth O’Regan more than expected).

Fields of papers citing papers by Ruth O’Regan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruth O’Regan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruth O’Regan. The network helps show where Ruth O’Regan may publish in the future.

Co-authorship network of co-authors of Ruth O’Regan

This figure shows the co-authorship network connecting the top 25 collaborators of Ruth O’Regan. A scholar is included among the top collaborators of Ruth O’Regan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruth O’Regan. Ruth O’Regan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Strawderman, Myla, Derick R. Peterson, Yue Li, et al.. (2025). Biology is Queen: The Oncotype DX 21-Gene Recurrence Score Has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer. Annals of Surgical Oncology. 32(13). 9825–9835.

Tarantino, Paolo, H. S. Rugo, Joyce O’Shaughnessy, et al.. (2025). Characteristics of real-world NATALEE- and monarchE-eligible populations with HR+/HER2− early breast cancer: a United States Electronic Health Records database analysis. ESMO Open. 10(6). 105304–105304.

Mirmosayyeb, Omid, et al.. (2024). Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer. Cancers. 16(3). 619–619. 17 indexed citations

Baran, Andrea, Ruth O’Regan, Huina Zhang, et al.. (2024). Effect of Breast Cancer Receptor Subtypes and CSF Cytology Status on Survival of Patients With Leptomeningeal Disease. Clinical Breast Cancer. 25(1). 65–74.e5.

Baran, Andrea, Huina Zhang, Ruth O’Regan, et al.. (2024). Effect of breast cancer receptor subtypes and CSF cytology status on survival for patients with leptomeningeal disease.. Journal of Clinical Oncology. 42(16_suppl). 2025–2025.

Loi, Samantha M., Erica Stringer-Reasor, Jean‐Sébastien Frenel, et al.. (2024). 235MO Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in younger patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE. Annals of Oncology. 35. S310–S311. 1 indexed citations

O’Regan, Ruth, Gini F. Fleming, Prudence A. Francis, et al.. (2023). Abstract GS1-06: Evaluation of the Breast Cancer Index in premenopausal women with early-stage HR+ breast cancer in the SOFT trial. Cancer Research. 83(5_Supplement). GS1–6. 2 indexed citations

Hall, Wyatte C., et al.. (2023). Creating the High School Pipeline for Future Deaf Scientists in Academic Medicine. Academic Medicine. 98(11). 1235–1235.

Zhang, Ziwei, Cristina I. Truica, Anne Blaes, et al.. (2022). Identification of exosome protein biomarkers in patients with advanced hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.. Journal of Clinical Oncology. 40(16_suppl). e13014–e13014. 2 indexed citations

10.

Denduluri, Neelima, Kathy D. Miller, & Ruth O’Regan. (2018). Using a Neoadjuvant Approach for Evaluating Novel Therapies for Patients With Breast Cancer. American Society of Clinical Oncology Educational Book. 38(38). 47–55. 5 indexed citations

11.

Arciero, Cletus A., Jing Yang, Limin Peng, et al.. (2017). African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages. Breast Cancer Research and Treatment. 166(3). 743–755. 16 indexed citations

12.

Qin, Yunlong, Kartik Aysola, Gabriela Oprea, et al.. (2014). A Novel Pathway that Links Caveolin-1 Down-Regulation to BRCA1 Dysfunction in Serous Epithelial Ovarian Cancer Cells. PubMed. 1(1). 8 indexed citations

13.

Paplomata, Elisavet, Amelia Zelnak, & Ruth O’Regan. (2013). Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Research and Treatment. 140(3). 453–462. 78 indexed citations

14.

Hagen, Katie R., Xiangbin Zeng, Mi‐Young Lee, et al.. (2013). Silencing CDK4 radiosensitizes breast cancer cells by promoting apoptosis. Cell Division. 8(1). 10–10. 38 indexed citations

15.

Lund, Mary Jo, Monica Rizzo, Harvey L. Bumpers, et al.. (2010). Using National Quality Forum Breast Cancer Indicators to Measure Quality of Care for Patients in an AVON Comprehensive Breast Center. The Breast Journal. 16(3). 240–244. 10 indexed citations

16.

Graham, Tisheeka, Valerie Odero‐Marah, Adeboye O. Osunkoya, et al.. (2008). IGF-I-dependent upregulation of ZEB1 expression drives EMT in human prostate cancer cells in vitro. Cancer Research. 68. 3585–3585. 1 indexed citations

17.

Lund, Mary Jo, Katrina F. Trivers, Peggy L. Porter, et al.. (2008). Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Research and Treatment. 113(2). 357–370. 336 indexed citations

18.

O’Regan, Ruth. (2005). The Fall of Tamoxifen?. 0(0). 1–1. 3 indexed citations

19.

Kaklamani, Virginia & Ruth O’Regan. (2004). New targeted therapies in breast cancer. Seminars in Oncology. 31(2 Suppl 4). 20–25. 40 indexed citations

20.

Eustace, Stephen, et al.. (1995). Primary multifocal skeletal Hodgkin’s disease confined to bone. Skeletal Radiology. 24(1). 61–63. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact